## **Pirenoxine**

ピレノキシン

 $C_{16}H_8N_2O_5$ : 308.25

1-Hydroxy-5-oxo-5*H*-pyrido[3,2-*a*]phenoxazine-3-carboxylic acid [*1043-21-6*]

Pirenoxine, when dried, contains not less than 98.0% of  $C_{16}H_8N_2O_5$ .

**Description** Pirenoxine occurs as a yellow-brown powder. It is odorless, and has a slightly bitter taste.

It is very slightly soluble in dimethylsulfoxide, and practically insoluble in water, in acetonitrile, in ethanol (95), in tetrahydrofuran and in diethyl ether.

Melting point: about 250°C (with decomposition).

**Identification** (1) Dissolve 2 mg of Pirenoxine in 10 mL of phosphate buffer solution, pH 6.5, add 5 mL of a solution of L-ascorbic acid (1 in 50), and shake vigorously: a dark purple precipitate is formed.

- (2) Determine the absorption spectrum of a solution of Pirenoxine in phosphate buffer solution, pH 6.5 (1 in 200,000) as directed under the Ultraviolet-visible Spectrophotometry, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.
- (3) Determine the infrared absorption spectrum of Pirenoxine, previously dried, as directed in the potassium bromide disk method under the Infrared Spectrophotometry, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.
- **Purity** (1) Heavy metals—Proceed with 1.0 g of Pirenoxine according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).
- (2) Related substances—Dissolve 0.010 g of Pirenoxine in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 3 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform the test with 5  $\mu$ L each of the sample solution and the standard solution as directed under the Liquid Chromatography according to the following conditions. Determine each peak area of both solutions by the automatic integration method: the total area of the peaks other than the peak of pirenoxine from the sample solution is not larger than the peak area of pirenoxine from the standard solution.

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 230 nm).

Column: A stainless steel column about 4 mm in inside diameter and about 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 to  $10 \mu m$  in particle diameter).

Column temperature: A constant temperature of about 35°C

Mobile phase: Dissolve 1.39 g of tetra *n*-butylammonium chloride and 4.5 g of disodium hydrogenphosphate 12-water in 1000 mL of water, and adjust the pH to 6.5 with phosphoric acid. To 700 mL of this solution add 200 mL of acetonitrile and 30 mL of tetrahydrofuran, and mix.

Flow rate: Adjust the flow rate so that the retention time of pirenoxine is about 10 minutes.

Selection of column: Dissolve 3 mg of Pirenoxine and 0.016 g of methyl parahydroxybenzoate in 100 mL of the mobile phase. Proceed with 5  $\mu$ L of this solution under the above operating conditions, and calculate the resolution. Use a column giving elution of pirenoxine and methyl parahydroxybenzoate in this order with the resolution between these peaks being not less than 2.0.

Detection sensitivity: Adjust the detection sensitivity so that the peak height of pirenoxine obtained from  $5 \mu L$  of the standard solution is between 5 mm and 10 mm.

Time span of measurement: About 3 times as long as the retention time of pirenoxine.

Loss on drying Not more than 1.5% (0.5 g, in vacuum, 80°C, 3 hours).

Residue on ignition Not more than 0.15% (1 g).

Assay Weigh accurately about 0.1 g of Pirenoxine, previously dried, dissolve in 140 mL of dimethylsulfoxide by heating on a water bath. After cooling, add 30 mL of water, and titrate immediately with 0.02 mol/L sodium hydroxide VS (potentiometric titration). Perform a blank determination, and make any necessary correction.

Each mL of 0.02 mol/L sodium hydroxide VS = 6.165 mg of  $C_{16}H_8N_2O_5$ 

Containers and storage Containers—Tight containers.

## Pivmecillinam Hydrochloride

塩酸ピブメシリナム

 $C_{21}H_{33}N_3O_5S.HCl: 476.03$ 

2,2-Dimethylpropanoyloxymethyl (2S,5R,6R)-6-[(azepan-1-ylmethylene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate monohydrochloride [32887-03-9]

Pivmecillinam Hydrochloride conforms to the requirements of Pivmecillinam Hydrochloride in the Requirements for Antibiotic Products of Japan.

**Description** Pivmecillinam Hydrochloride occurs as a white to yellowish white crystalline powder.

It is very soluble in methanol, freely soluble in water and in ethanol (99.5), and practically insoluble in diethyl ether.